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Our understanding of the molecular properties of kainate receptors and their involvement in synaptic phys-
iology has progressed significantly over the last 30 years. A plethora of studies indicate that kainate receptors
are important mediators of the pre- and postsynaptic actions of glutamate, although the mechanisms under-
lying such effects are still often a topic for discussion. Three clear fields related to their behavior have
emerged: there are a number of interacting proteins that pace the properties of kainate receptors; their
activity is unconventional since they can also signal through G proteins, behaving like metabotropic recep-
tors; they seem to be linked to some devastating brain diseases. Despite the significant progress in their
importance in brain function, kainate receptors remain somewhat puzzling. Here we examine discoveries
linking these receptors to physiology and their probable implications in disease, in particularmood disorders,
and propose some ideas to obtain a deeper understanding of these intriguing proteins.A Historical Overview
Most excitatory synapses in the brain use the amino acid gluta-
mate as a neurotransmitter. Since the excitatory properties of
glutamate were postulated nearly 40 years ago, an extraordinary
wealth of data has accumulated on the types of synaptic re-
sponses triggered by this neurotransmitter. Glutamate acts on
a variety of receptor proteins, initially classified by the mecha-
nisms that they use to transmit signals (i.e., metabotropic versus
ionotropic). A more precise specification of ionotropic receptors
into three types was subsequently proposed, based on the
agonist that activates or binds to them. Thus, AMPA, kainate,
and NMDA receptors (AMPARs, KARs, and NMDARs, respec-
tively) are recognized as the main effectors of glutamate at syn-
apses. We now know that this classification is misleading, since
there is certain cross-reactivity between agonists and receptors
and only recently have some new compounds enriched the phar-
macological armamentarium (see Jane et al., 2009 for a review).
Unlike other receptors, studies of KARs suffered from the lack
of specific compounds to activate or block these proteins. First
of all, kainate is derived from the seaweed known as ‘‘kaininso’’
in Japanese, and it is a mixed agonist that can also activate
AMPARs. This fact led to certain misinterpretations of the role
of KARs in the brain and, even nowadays, some related errors
can be detected in the literature. In addition, the prototypical
AMPAR agonist, AMPA, can also activate diverse KARs. Like
the AMPARs and NMDARs, KARs are tetrameric combinations
of a number of subunits: named GluK1, GluK2, GluK3, GluK4,
and GluK5 (previously known as GluR5–GluR7 and KA1 and
KA2, respectively). Of these, GluK1–GluK3 may form functional
homomeric or heteromeric receptors, while GluK4 and GluK5
only participate in functional receptors when partnering any of
the GluK1–GluK3 subunits. The structural repertoire of KAR sub-
types is further extended by editing of the GluK1 and GluK2
receptor subunit pre-mRNAs at the so-called Q/R site of the sec-
ond membrane domain. More isoforms also arise from the alter-
native splicing of GluK1–GluK3 subunits, while GluK4 and GluK5
seem not to be subjected to this type of processing.292 Neuron 80, October 16, 2013 ª2013 Elsevier Inc.The absence of specific antibodies against different KAR
subunits has been a significant limitation in terms of exploring re-
ceptor distribution. Thus, most of the information regarding their
tissue expression comes from in situ hybridization studies that,
although informative, cannot reveal the subcellular distribution
of a given subunit. Relatively good and specific antisera against
the KAR subunits GluK2/3 and GluK5 are now available,
although not all work properly in immunocytochemistry. Never-
theless, some general rules could be extracted from all these
studies. GluK2 subunits are mostly expressed by principal cells
(hippocampal pyramidal cells; both hippocampal and cerebellar
granule cells; cortical pyramidal cells), while GluK1 is mainly pre-
sent in hippocampal and cortical interneurons (Paternain et al.,
2003) as well as in Purkinje cells and sensory neurons. GluK3
is poorly expressed, appearing in layer IV of the neocortex and
dentate gyrus in the hippocampus (Wisden and Seeburg,
1993). GluK4 is mainly expressed in CA3 pyramidal neurons,
dentate gyrus, neocortex, and Purkinje cells, while GluK5 is ex-
pressed abundantly in the brain (Bahn et al., 1994).
The functional description of KARs within the CNS (Lerma
et al., 1993) and themolecular identification of KAR subunits rep-
resented real breakthroughs in the study of these receptors, as
did the discovery that GYKI53655, a 2,3, benzodiazepine, was
essentially inactive at KARs (Paternain et al., 1995; Wilding and
Huettner, 1995) (with the exception of a few particular assem-
blies on which it may act at high concentrations; see Perrais
et al., 2009), and constitute the foundation upon which our
understanding of KARs has been constructed.
On the basis of the data collected over the last 30 years of
research, how do we now envisage the physiological role of
KARs? A comprehensive analysis of the profuse yet often
controversial literature on KARs leads us to conclude that these
receptors play significant roles in the brain at threemain levels. In
the first place, they mediate postsynaptic depolarization and
they are responsible for carrying some of the synaptic current,
although this only happens at some synapses. Second, KARs
can modulate the synaptic release of neurotransmitters such
Table 1. The Kainate Receptor Interactome
Interactor KAR Subunit Direct Role References
Actinfilin GluK2 Yes Receptor degradation through ubiquitination Salinas et al., 2006
b-catenin GluK2 No Plasma membrane dynamics Coussen et al., 2005
Cadherin GluK2 ND Receptor trafficking/subcellular localization Coussen et al., 2005
Calcineurin GluK2 Yes Ca2+-regulation of channel function Coussen et al., 2005
Calmodulin GluK2 Yes ND Coussen et al., 2005
Contactin GluK2 Yes ND Coussen et al., 2005
COPI GluK5 Yes Receptor trafficking Vivithanaporn et al., 2006
Dynamin-1 GluK2 Yes ND Coussen et al., 2005
Dynamitin GluK2 Yes ND Coussen et al., 2005
14.3.3 GluK1, GluK2, GluK5 Yes Receptor trafficking Coussen et al., 2005; Vivithanaporn et al., 2006
4.1N GluK1, GluK2 Yes Receptor trafficking Copits and Swanson, 2013b
GRIP GluK2, K5 Yes Receptor trafficking Hirbec et al., 2003
KRIP6 GluK2 Yes Receptor gating Laezza et al., 2007
NETO1 GluK1-3 Yes Ion channel function Zhang et al., 2009; Copits et al., 2011;
Straub et al., 2011a; Tang et al., 2011
NETO2 GluK1-3 Yes Ion channel function Zhang et al., 2009; Copits et al., 2011
NSF GluK2 Yes ND Coussen et al., 2005
PICK1 GluK2, GluK5 Yes Receptor trafficking Hirbec et al., 2003
Profillin II GluK2 Yes Receptor trafficking Coussen et al., 2005; Mondin et al., 2010
PSD95 GluK2, GluK5 Yes Alters receptor function by reducing
desensitization
Garcia et al., 1998
SAP102 GluK2, GluK5 Yes Receptor clustering; Garcia et al., 1998
SAP90 GluK2, GluK5 Yes Receptor clustering; modulation of
desensitization
Garcia et al., 1998
SAP97 GluK2 Yes Receptor clustering Garcia et al., 1998
SNAP25 GluK5 ND Receptor trafficking Selak et al., 2009
Spectrin GluK2 Yes ND Coussen et al., 2005
Syntenin GluK1, GluK2 Yes Plasma membrane dynamics Hirbec et al., 2003
VILIP-1 GluK2 Yes ND Coussen et al., 2005
VILIP-3 GluK2 Yes ND Coussen et al., 2005
ND, not determined.
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influential role in thematuration of neural circuits during develop-
ment. These roles are frequently fulfilled in an unconventional
way given that KARs can signal by activating a G protein,
behaving more like a metabotropic receptor than an ion channel.
This noncanonical signaling is totally unexpected considering
that the three iGluRs share a common molecular design, as
recently revealed by their crystal structure (Mayer, 2005; Furu-
kawa et al., 2005; Gouaux, 2004).
It is difficult to do justice to the literature generated on KARs
over the years in the short space available, and indeed, there
are several reviews that have described many of the molecular,
biophysical, pharmacological, and functional aspects of these
receptors (Rodrigues and Lerma, 2012; Contractor et al., 2011;
Lerma et al., 2001, Lerma, 2003, 2006; Copits and Swanson,
2012; Vincent and Mulle, 2009; Coussen and Mulle, 2006; Pin-
heiro and Mulle, 2006; Tomita and Castillo, 2012; Jaskolski
et al., 2005; Matute, 2011). Hence, in this Review we will focus
primarily on the data that have influenced our notion of KAR func-tion and the wealth of new data available implicating KARs in
brain pathology.
The Explosion of KAR Interacting Proteins
To date, and likemany other receptors and channels, a whole set
of proteins have been identified that can interact with KAR sub-
units (Table 1). Indeed, the identification of these proteins has
changed our view on how KARs function and provided insight
into the discrepancies between native and recombinant KAR
properties. While the exact role of these interactions still remains
to be unambiguously established, the role of KARs in physiology
will be difficult to understand without taking into account the
contribution of these proteins. For instance, KARs and many of
these proteins seem to undergo transient interactions that pro-
mote receptor trafficking, regulating their surface expression.
PDZmotif-containing proteins such as postsynaptic density pro-
tein 95 (PSD-95), protein interacting with C kinase-1 (PICK1), and
glutamate receptor interacting protein (GRIP) seem to be rele-
vant for the stabilization of KARs at the synaptic membraneNeuron 80, October 16, 2013 ª2013 Elsevier Inc. 293
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nus of KAR subunits are also present in other glutamate recep-
tors. Thus, these interacting proteins are not selective for
KARs. Although interactions with PDZ domains cannot entirely
account for the subcellular distribution of KARs, the interaction
with PDZ proteins produce apparently different outcomes for
these receptors, as these proteins prevent AMPAR internaliza-
tion but facilitate KAR internalization (Hirbec et al., 2003).
It was recently demonstrated that the SNARE protein SNAP-
25 is a KAR-interacting protein (Selak et al., 2009). In MF-CA3
synapses, activity-dependent stimulation of PKC intensifies
this interaction and triggers the internalization of KARs, leading
to a specific long-term depression (LTD) of KAR-mediated
synaptic transmission. Interestingly, these results implied that
SNAP25, classically regarded as a member of the exocytotic
machinery, may be also involved in endocytosis (Selak et al.,
2009). This view has been recently supported by a report
defining a role for SNAP25 in clathrin-dependent endocytosis
at conventional synapses (Zhang et al., 2013). KARs at these
synapses may also contain GluK2 subunits and, recently, it
was proposed that this mechanism of LTD requires the synergis-
tic SUMOylation of GluK2 subunits, initiated by PKC phosphor-
ylation (Chamberlain et al., 2012). This newmechanism expands
the repertoire of events associated with synaptic plasticity.
The possibility of modifying information transfer at this level
has been further illustrated by the recent observation that
CaMKII-mediated phosphorylation of GluK5 subunits also de-
presses a KAR-mediated synaptic component at CA3 synapses
(Carta et al., 2013). A spike timing-dependent plasticity protocol,
known to activate CaMKII in a number of synapses and induce
AMPAR LTP, induces phosphorylation of GluK5-containing
receptors in MF-CA3 synapses, resulting in LTD of the KAR-
mediated synaptic component. Rather than involving endocy-
tosis of KARs, this depression is evoked by the lateral diffusion
of these receptors upon uncoupling of the PSD-95 scaffolding
protein at the postsynaptic density (Carta et al., 2013; see also
Copits and Swanson, 2013a).
Additional proteins that interact and directly modulate the
properties of KARs have also been identified. These include pro-
teins such as kainate receptor interacting protein for GluR6
(KRIP6; Laezza et al., 2007), a protein that belongs to the BTB/
kelch family and that binds to a C-terminal motif distinct to the
PDZ binding motif. Coexpression of KRIP6 with GluK2 reduces
both the peak current and steady-state desensitization in recom-
binant systems, as well as that of native KARs. Interestingly,
KRIP6 does not affect the surface expression of GluK2 recep-
tors, indicating that the interaction with this protein only affects
channel gating. Another BTB/kelch family member, actinfilin, is
also thought to interact with GluK2 subunits (Salinas et al.,
2006), this protein promoting the degradation of GluK2 receptors
by acting as a scaffold to link this subunit to the E3 ubiquitin-
ligase complex. In this way, actinfilin regulates the synaptic
expression of receptors containing GluK2 (Salinas et al., 2006),
although more work will be necessary to reveal what is the phys-
iological impact of these BTB/kelch proteins. For instance, it is
known that KRIP6 can interact with PICK1, forming clusters
that lack GluK2 and preventing the mutual regulation of GluK2
containing KARs (Laezza et al., 2008).294 Neuron 80, October 16, 2013 ª2013 Elsevier Inc.A number of studies have identified trafficking and targeting
motifs in KAR subunits and increased our knowledge of the
mechanisms controlling KAR targeting and surface expression
(see reviews by Pinheiro and Mulle, 2006 and Contractor et al.,
2011). However, many other aspects of KAR biology still remain
to be defined. For instance, many of the mechanisms supporting
the polarized targeting of KARs to different neuronal populations
are unknown.
Recently, two integral membrane proteins have been identi-
fied that seem to be true auxiliary subunits of KARs (Zhang
et al., 2009; Straub et al., 2011a; Tang et al., 2011). Neuropilin
Tolloid-like 1 and Neuropilin Tolloid-like 2 (Neto1 and Neto2)
are auxiliary proteins of native KARs that exert an important influ-
ence on their function. Indeed, these proteins radically alter the
gating properties of KARs, accounting for a number of previously
unexplained properties of these receptors (see Copits and
Swanson, 2012; Lerma, 2011; Tomita and Castillo, 2012 for
recent reviews). Neto1 and Neto2 share an identical and unique
domain structure, representing a novel subfamily of transmem-
brane proteins containing CUB and LDLa domains. Neto1 was
first identified as a protein that interacts with the NMDA receptor
(Ng et al., 2009), although a number of studies then illustrated
that it has a more striking influence on the function of KARs. In
general, the coexpression of Neto1 and Neto2 with KARs in
recombinant systems alters the gating properties of the latter.
The most obvious effect is that the onset of the desensitization
of kainate-evoked responses decelerates (Copits et al., 2011;
Straub et al., 2011b; Fisher and Mott, 2013), while recovery
from the desensitized state accelerates. This modulation implies
that the kainate-induced steady current persists for longer
periods in the presence of an agonist (e.g., Fisher and Mott,
2013). This effect is evident for all subunits and reconciles the
properties of recombinant receptors with the reported action of
kainate in more physiological preparations, where it behaves
as a strong depolarizing agent. Moreover, the rapid deactivation
of kainate-induced currents upon agonist removal is also decel-
erated in the presence of Neto, suggesting an increase in the
steady-state affinity of KARs when associated to Neto. Indeed,
equilibrium agonist affinity substantially increased in the pres-
ence of Neto, again reconciling the properties of recombinant
and native KARs.
A prominent feature of KAR-mediated excitatory postsynaptic
currents (EPSCKARs) is that they are characteristically slower and
smaller than AMPAR-mediated EPSCs (Castillo et al., 1997;
Vignes et al., 1998; Frerking et al., 1998). This cannot be antici-
pated from the properties of recombinant receptors, since single
KARs and AMPARs have similar affinity and activation-inactiva-
tion kinetics (see Lerma, 1997). A prominent perisynaptic locali-
zation of KARswas also ruled out (Castillo et al., 1997) and if both
receptor subtypes colocalize at the synapse, one would expect
similar kinetics for the KAR- and AMPAR-mediated synaptic re-
sponses. Although the subunit composition of KARs may have
an influence in EPSC kinetics (Contractor et al., 2001; Barberis
et al., 2008; Fernandes et al., 2009), no convincing explanation
for this discrepancy had been available until the discovery that
Neto proteins confer higher agonist affinity to KARs and impose
significantly slower deactivation kinetics. Curiously, the kinetics
of KARs imposed by Neto protein is remarkably similar to those
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A B Figure 1. Kinetic Similarities betweenNMDAR
and KARs
(A) NMDARs, AMPARs, and KARs coexist in Mossy
Fiber to CA3 neuron synapses.
(B) Synaptic responses mediated by AMPAR are
much faster than the KAR and NMDAR components,
as can be seen after their pharmacological isolation.
(C) Responses mediated by AMPARs, NMDARs, and
KARs are superimposed once scaled. Note how
KARs and NMDARs generate responses with a
remarkable similar onset and decay time courses.
(D) The slow time course of KARs is accounted for
by their interaction with Neto proteins. Note how
KAR-mediated EPSCs are accelerated in the Neto1
KO mice, approaching the characteristics of the
AMPAR-mediated component (records reproduced
with permission from Straub et al., 2011a).
(E) Participation of postsynaptic KARs to MF-CA3
synaptic transmission: averaged traces illustrate the
effect of KARs antagonist UBP310 on the depola-
rizing envelope (shaded area) induced by a train of
stimuli. KARs blockade reduces summation and
prevents neuron firing (spikes are shown truncated)
(from Pinheiro et al., 2013).
(F) CA3 pyramidal cell firing in response to a physi-
ological granule cell firing pattern of stimulation (ex-
tracted from an in vivo recording of a freely moving
mouse) in WT and a GluK2-deficient mouse,
revealing the contribution of postsynaptic KARs to
neuronal output (from Sachidhanandam et al., 2009).
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vation kinetics and that of the faster AMPARs provides adequate
timing for activation, since the Mg2+ blockade implies that
NMDAR activation would not be operative until sufficient mem-
brane depolarization is attained. In contrast, the functional signif-
icance of the slower kinetics of KARs is starting to be illustrated
by examples that provide comprehensive roles for such a
prolonged current in synaptic integration (Frerking and Ohliger-
Frerking, 2002; Goldin et al., 2007; Sachidhanandam et al.,
2009; Pinheiro et al., 2013; see Figure 1).
Another striking action of Neto1 and Neto2 is that association
with these proteins greatly reduces inward rectification of KAR-
mediated currents without modifying Ca2+ permeability (Fisher
and Mott, 2012). It seems that three positive charges (RKK) in
the C-terminal of Neto proteins preclude internal polyamine
blockade of KAR channel. This effect is reminiscent of stargazin
in AMPARs (Soto et al., 2007). However, the functional implica-
tion of this action remains to be defined.
Apart from the clear effect of Netos on KAR channel gating
and on current amplitudes (see Copits and Swanson, 2012), it
remains unclear whether Neto proteins are involved in KAR
targeting to the synapse, although there is weak evidence indi-
cating that this may be possible. Cultured hippocampal neurons
express native KARs, but these are not targeted to synapses
(Lerma et al., 1997). However, a small proportion of ESPCs
may be mediated by KARs when such cells are transfected
with Neto2 and GluK1, indicating that exogenous Neto2 may
target a small proportion of exogenous GluK1 to synapses
(Copits et al., 2011). Similar effects were observed in cerebellar
granule cells and with GluK2 (Zhang et al., 2009). However,
although GluK2 association with PSD95 is reduced in
Neto2 null mice (Tang et al., 2012), the lack of Neto2 expres-
sion does not prevent the presence of endogenous GluK1 orGluK2 in synaptic contacts, despite the fact that synaptic
KARs are normally associated with Netos in hippocampal
slices. Indeed, KAR-mediated EPSCs in brain slices display
distinct kinetics in Neto-deficient animals and EPSCKARs are
present in mice even deficient for the two Neto proteins, yet
with fast kinetics, consistent with the idea that Netos are not
key elements in the targeting of KARs to the synapse (Tang
et al., 2011).
From these data, it is clear that Netos exert an important influ-
ence on KARs, which may vary depending on the subunit com-
bination. However, Neto proteins are not specific to KARs.
Indeed, Neto1 was initially identified as a NMDAR interactor.
While Neto2 was originally thought to partner KARs only, it was
recently reported to also interact with distant proteins, such as
the neuron-specific K+-Cl cotransporter KCC2, which is essen-
tial to maintain Cl homeostasis in neurons (Ivakine et al., 2013).
These data raise the possibility that Neto proteins play a more
wide-ranging role than initially anticipated. Nevertheless, the
interesting question that remains to be answered is whether
the association of Neto1/2 with KARs could be regulated by
physiological signals, and under what circumstances this
occurs. Since KARs are fully operational in the absence of
Neto, it is possible that two populations of KARs might exist,
those with and without Neto probably fulfilling complementary
functional roles.
Recently, the group of Maricq has identified in the worm
C. elegans SOL-2, a CUB-domain protein that associates with
both the related auxiliary subunit SOL-1 and with the GLR-1
AMPAR (Wang et al., 2012). Like Neto1, SOL-2 contributes to
the kinetics of receptor desensitization and is an essential
component of AMPAR complexes at worm synapses. These
data indicate that several different interacting proteins could
form the receptor complex at synapses.Neuron 80, October 16, 2013 ª2013 Elsevier Inc. 295
Figure 2. Kainate Receptors Signal through
Two Different and Independent Pathways
On the one hand, the gating of the channel
(canonical pathway, a) is responsible for mem-
brane depolarization and the synaptic responses
(b) and probably for the facilitation of neurotrans-
mitter release at some synapses. These receptors
bear ancillary proteins, like Neto. On the other
hand, KARs activate G proteins (c), signaling
through the stimulation of phospholipase C and
PKC in a manner independent of ion flux. It is
unknown whether these receptors are coupled to
Neto proteins and whether they require an inter-
mediate protein to couple to G protein. The main
effects so far documented are: the increase in
neuronal excitability through the inhibition of
afterhypopolarizing current (IAHP, d), leading to an
increase in the firing frequency of these neurons
(e); the facilitation and inhibition of transmitter
release, probably through the modulation of cal-
cium currents (ICa
2+, f); and their role in the matu-
ration of neuronal circuits during development.
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One unique feature of KARs is that their channel gating requires
external monovalent cations and anions. This ion-dependent
channel gating differentiates KARs from other ligand-gated
channels, including the closely related NMDARs and AMPARs
(Paternain et al., 2003; Bowie, 2002; see Bowie, 2010 for a
review). Indeed, crystallographic studies have revealed the exis-
tence of an ion binding pocket in KAR subunits (Plested and
Mayer, 2007; Plested et al., 2008). The absolute requirement of
ion binding for channel opening indicates that KAR activity
would be abolished if this binding site remained unoccupied,
prompting the suggestion that this site might be used as a target
for specific allosteric modulation of KARs by external agents.
The question as to what might be the physiological role of
such a strict dependence of the channel gate has not been
answered yet but prompted some possibilities. For instance,
under intense neuronal activity, a situation under which external
Na+ levels drop, activation of KARswould be limited, constituting
a brake for tissue damage. Indeed, a large fraction of KARs
seems to have unoccupied the cation binding site at physiolog-
ical salt concentrations, making them insensitive to activation by
released glutamate (Plested et al., 2008). Much work remains to
be done to figure out whether this fraction of incompetent KARs
could bemodulated up and down as away to regulate theweight
of these receptors in, for instance, synaptic transmission.
A Receptor with Two Modes of Signaling
High-resolution structural analysis has revealedmany similarities
between the three glutamate receptor families. However, unlike
AMPA and NMDA receptors, KARs appear to also signal through296 Neuron 80, October 16, 2013 ª2013 Elsevier Inc.an unconventional metabotropic mecha-
nism involving G proteins and second
messengers at inhibitory CA1 hippocam-
pal synapses (Rodrı´guez-Moreno et al.,
1997; Clarke et al., 1997). This signaling
follows presynaptic inhibition of GABA
release and is dependent on G protein
activation and PKC activity (Rodrı´guez-Moreno and Lerma, 1998; Rodrı´guez-Moreno et al., 2000). Later,
this nonconventional mode of signaling was compellingly estab-
lished in dorsal root ganglion neurons and was shown to be
independent of ion flux (Rozas et al., 2003). Since then, an
increasing number of metabotropic actions triggered by KARs
have been described in many cell types and in different regions
of the CNS, particularly in association with the presynaptic con-
trol of neurotransmitter release or the postsynaptic regulation of
neuronal excitability (see Rodrigues and Lerma, 2012 for a recent
review and Figure 2). However, key aspects of the molecular
mechanisms underlying this noncanonical signaling still remain
unclear, including how KARs activate G proteins to trigger these
effects and what determines the mode of action of KARs
(i.e., conventional ionotropic versus noncanonical metabotropic
signaling).
The evidence for a direct interaction between KARs and G
proteins is limited. Prior to describing the metabotropic behavior
of KARs, the Pertussis toxin (PTx)-sensitive binding of an agonist
to goldfish-purified KARs was demonstrated biochemically,
providing a link between KARs and PTx-sensitive proteins (Zie-
gra et al., 1992).While similar PTx-sensitive KAR agonist-binding
was also observed in hippocampal membranes (Cunha et al.,
1999), this kind of interaction does not seem to be that related
to the functional signal transduced by KAR activation through
G protein activity. It is expected that undergoing proteomic anal-
ysis of KAR subunits identify partners that could account for the
coupling between an ion channel receptor and a G protein.
Initially, it was unclear which subunits might engage this activ-
ity and, still, the search to identify the KAR subunit that mediates
this noncanonical signaling is not free of controversy. In dorsal
Neuron
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GluK5 subunits, noncanonical signaling was dependent on
GluK1 rather than GluK5 (Rozas et al., 2003). Subsequent
studies found that KAR-mediated modulation of IAHP, an action
provoked by the noncanonical signaling of KARs (Melyan et al.,
2002), was absent in GluK2- (Fisahn et al., 2005) or GluK5-
(Ruiz et al., 2005) deficient mice. However, more recent studies
reported that noncanonical signaling persisted in GluK5 and
GluK4–GluK5 knockout (KO) animals (Fernandes et al., 2009).
Indeed, expression of GluK1 in SHSY5 neuroblastoma cells
was sufficient to reconstitute metabotropic activity of KARs, as
evaluated by the G protein and PKC activation inducing internal-
ization of KARs from the membrane (Rivera et al., 2007). Recent
experiments confirmed the involvement of GluK1 in the metabo-
tropic control of glutamate release (Segerstra˚le et al., 2010; Sal-
men et al., 2012). However, a biochemical interaction between
GluK5 and a Gaq protein was identified in biochemical experi-
ments (Ruiz et al., 2005). These data would in principle indicate
that the subunit interacting with G proteins might be GluK5,
either directly or indirectly. There are additional issues that
appear at odds with this idea. The involvement of Gq protein
does not fit with the PTx sensitivity of the metabotropic actions
of KARs described to date (see Rodrigues and Lerma, 2012
and references therein) but, rather, the PTx sensitivity suggests
that Gi or Go proteins are likely to be involved in themetabotropic
actions of KARs. However, the concomitant involvement of PLC
and PKC in most of the metabotropic effects described to date
rules out the participation of Gi, leaving the Go protein as the
only strong candidate to mediate these effects (e.g., Rozas
et al., 2003). Nevertheless, some effects induced by KA are
contingent on the inhibition of adenylate cyclase and the subse-
quent reduction in cAMP would involve Gi protein activation, as
also described (Gelsomino et al., 2013; Negrete-Dı´az et al.,
2006). Available data clearly show that subunit composition
alone cannot define the signaling mode triggered by KARs,
pointing to interacting partners as candidates likely to determine
the mode of action of KARs. However, the existence of proteins
that functionally couple KARs and G proteins remains to be
demonstrated.
It should be also taken into account that some at odds data
has been published pointing out that at least part of the nonca-
nonical signaling triggered by KARs may be indirect (Lourenc¸o
et al., 2011). Regardless of the specific mechanisms, it is now
clear that KARs can no longer be considered simply as ligand-
gated ion channels. The increasing number of activities known
to be mediated by KARs through this noncanonical signaling,
as described below, indicates that this dual signaling is one of
the main factors underlying the diverse actions of KARs reported
over the years.
Roles in Synaptic Transmission and Network Excitability
Postsynaptic Kainate Receptors
Unlike AMPAR-mediated currents, the activation of postsynaptic
KARs by synaptically released glutamate yields small amplitude
EPSCs, with slow activation and deactivation kinetics (see
Figure 1; Castillo et al., 1997). Moreover, while AMPARs and
NMDARs are localized to the postsynaptic density of the vast
majority of glutamatergic synapses in the brain, EPSCsmediatedby KARs have only been found in a few central synapses, such as
in MF to CA3 pyramidal neurons (Castillo et al., 1997; Vignes and
Collingridge, 1997), the contacts between Schaffer collaterals
and CA1 hippocampal interneurons (Cossart et al., 1998; Frerk-
ing et al., 1998), between parallel fibers and Golgi cells in the
cerebellum (Bureau et al., 2000), at thalamocortical connections
(Kidd and Isaac, 1999), in the basolateral amygdala (Li and
Rogawski, 1998), in the synapses between afferent sensory
fibers and dorsal horn neurons in the spinal cord (Li et al.,
1999), and those of parallel fibers and cerebellar Golgi cells
(Bureau et al., 2000). In all these synapses, the characteristic
slow kinetics is a predominant feature of the EPSCKAR, probably
providing integrative capacities to information transfer clearly
unfulfilled by other glutamate receptors (Frerking and Ohliger-
Frerking, 2002; Pinheiro et al., 2013). For instance, O-LM inter-
neurons are a somatostatin interneuronal subtype at the stratum
oriens that processes glutamatergic inputs through KARs,
which endow these cells with the ability to follow inputs at the
theta frequency (Goldin et al., 2007). In addition, recent data indi-
cate that GluK1-containing KARs in a subset of stratum radiatum
interneurons mediate feedforward inhibition of pyramidal cells.
The output of these interneurons is enhanced during both low-
frequency-evoked stimulation and natural-type firing patterns.
During this activity, the threshold for the induction of theta-burst
LTP is raised. In this way, such KAR-mediated input promotes a
shift in the dynamics of synaptic transmission in favor of inter-
neuronal output onto CA1 pyramidal neurons (Clarke et al.,
2012).
A striking impact on neuronal excitability of postsynaptic
KARs, acting through their noncanonical signaling, is provided
by the regulatory action of the slow afterhyperpolarization cur-
rent (IsAHP: Melyan et al., 2002, 2004). The IsAHP activates upon
bursts of action potentials and it is generated by voltage-sensi-
tive Ca2+-dependent K+ channels. It has a slow decay time as
it may last for several seconds, it is activated in proportion to
the number and frequency of action potentials (Lancaster and
Adams, 1986), and it underlies spike frequency adaptation
(Figure 2). At Schaffer-CA1 pyramidal cell synapses, at which
no EPSCKAR has been documented (Lerma et al., 1997; Castillo
et al., 1997; Frerking et al., 1998; Cossart et al., 1998), nanomolar
concentrations of KA cause long-lasting inhibition of IAHP
through the direct activity of KARs. This effect is mimicked by
synaptic glutamate released from excitatory afferents at the
CA1 synapses (Melyan et al., 2004; Chamberlain et al., 2013).
Pharmacological evidence indicates that this inhibition involves
the noncanonical signaling engaging Gi/o protein and PKC acti-
vation (Melyan et al., 2002) and probably PKA and downstream
activation of MAP kinases (Grabauskas et al., 2007). The inhibi-
tion of both the slow and medium IAHP by KAR activation in-
creases the firing frequency of these neurons, largely enhancing
circuit excitability (Fisahn et al., 2005; Ruiz et al., 2005). Like
KAR-mediated EPSCs, inhibition of IAHP has been observed in
MF-CA3 pyramidal cell synapses (Ruiz et al., 2005; Fisahn
et al., 2005) and, therefore, both signaling modes can coexist
within the same synapses. Thus, a short train of stimuli to the
mossy fibers could not only directly depolarize the postsynaptic
membrane but also increase neuronal excitability by prevent-
ing spike adaptation. Interestingly, both the ionotropic andNeuron 80, October 16, 2013 ª2013 Elsevier Inc. 297
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GABAergic IPSCsA B Figure 3. Presynaptic KARs Modulate
Synaptic Neurotransmitter Release in a
Bidirectional Manner and Both Inotropic and
Noncanonical Metabotropic Activity Are
Involved
(A) In the mossy fiber to CA3 synapses, activation
of KARs is responsible of part of the frequency
facilitation, such that the inclusion of a KAR
antagonist reduces the synaptic responses to the
second and subsequent stimuli but not the first
EPSC. At the bottom of each panel, the variation in
synaptic current charge (DQ) due to the activation
of KARs is indicated.
(B) Bidirectional modulation of evoked IPSCs by
KARs. Superimposed traces illustrating evoked
IPSCs obtained under control conditions (black traces) and in the presence of a KAR inhibitor (UBP302) (blue traces) in slices untreated or treated with D,L-TBOA,
an inhibitor of glutamate reuptake (based on Bonfardin et al., 2010). In the first case, GABA release is facilitated by tonic activity of KARs, while in the second
(larger concentrations of extracellular glutamate) GABA release is inhibited.
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independent of each other (Rozas et al., 2003), a result further
supported by the use of mice lacking individual KAR subunits
(Ruiz et al., 2005; Fernandes et al., 2009) or pharmacologically
antagonized ion channel activity (Pinheiro et al., 2013). This rein-
forces the idea that KARs may engage metabotropic and iono-
tropic signaling in an independent manner.
Together, the evidence provided so far demonstrates that
postsynaptic KARs regulate neuronal excitability both by pro-
ducing long-lasting depolarization and by inhibiting IAHP through
a segregated G protein-coupled pathway. The efficiency of
KARs in the regulation of neuronal excitability seems to rely on
repetitive synaptic activation rather than on single impulses, indi-
cating that postsynaptic KARs are designed to modulate the
temporal integration of excitatory circuits. Similarly, there is
now compelling evidence that KARs elicit sufficient charge
transfer to have a substantial impact on synaptic function wher-
ever they are expressed. For example, the kinetics of the EPSP
mediated by KARs is sufficiently slow to allow substantial tonic
depolarization during even modest presynaptic activity (Frerking
and Ohliger-Frerking, 2002; Sachidhanandam et al., 2009; see
Figure 1). But not only has the long ionotropic activity had an
impact on synaptic integration. The importance of the metabo-
tropic actions of KARs has also been recently put forward by
showing that the plastic changes in the KAR-mediated synaptic
component could modify the degree of inhibition of IAHP in CA3
pyramidal neurons. Chamberlain and associates (Chamberlain
et al., 2013) showed that induction of LTD of the KAR-mediated
EPSC induced by natural pattern of stimulation relieves the KAR-
induced inhibition of IAHP, resulting in further attenuation of
neuronal responses to subsequent inputs. These data indicate
that KARsmay exert a major role in regulating neuron excitability
and that although long-lasting plastic modulation of these recep-
tors does alter their ionotropic function, their concomitant
metabotropic activity becomes a dominant factor, at least
under certain experimental conditions such as high-frequency
(10–20 Hz) activity.
Also, KARs have been recently shown to be subject to homeo-
static plasticity (Yan et al., 2013) in that the KAR-mediated EPSC
at mossy fiber to cerebellar granule cell synapses was enhanced
after network activity blockade (either by TTx or genetically
removing AMPARs). This phenomenon relies on the enhanced
expression of GluK5 subunits that produces receptors with a298 Neuron 80, October 16, 2013 ª2013 Elsevier Inc.higher affinity for glutamate, efficiently maintaining spike gener-
ation at granule cells. Such effects should be explored at
different synapses given that this homeostatic regulation has
also been observed in climbing fibers to Purkinje cell synapses
(Yan et al., 2013), which may indicate it to be a more universal
mechanism than originally thought.
Presynaptic Kainate Receptors
The unconventional hypothesis that KARs could also play a role
as presynaptic modulators of neurotransmitter release was
prompted by the observation that the pharmacological activa-
tion of KARs modulated Ca2+-dependent glutamate release
from synaptosomes, which are structures devoid of somatoden-
dritic elements (Chittajallu et al., 1996). Since then, much effort
has been devoted to determine the presynaptic role of KARs
and it is now widely accepted that functional presynaptic KARs
play a crucial role in the control of neurotransmitter release
(Lerma, 2003). Indeed, it is now known that presynaptic KARs
modulate neurotransmitter release in a bidirectional manner,
not only at excitatory but also at inhibitory synapses.
KAR activation modulates GABAergic transmission in a com-
plex cellular and subcellular manner, and both depression and
facilitation of GABA release have been reported (Figure 3). The
question then arises as to which event takes preference over
the other and under what circumstances? Early indications of
KA-induced depression of inhibition in the hippocampus (Slo-
viter and Damiano, 1981) were confirmed by the demonstration
that KARs can inhibit GABA release (Rodrı´guez-Moreno et al.,
1997; Vignes et al., 1998). The depression of inhibition induced
was shown to be sensitive to PTx and to inhibitors of both PLC
and PKC, leading to the postulate that KARs participated in
unconventional events at presynaptic sites that most likely
involve a metabotropic signaling pathway rather than ion flux
(Rodrı´guez-Moreno and Lerma, 1998). This idea was later sup-
ported by measuring GABA release in synaptosomes (Cunha
et al., 1997, 2000; Perkinton and Sihra, 1999) and it has been
observed in other structures such as the amygdala (e.g., Braga
et al., 2004), neocortex (Ali et al., 2001), globus pallidus (Jin
and Smith, 2007), and hypothalamic supraoptic nucleus (Bonfar-
din et al., 2010). However, CA1 interneurons become overacti-
vated by exogenous KA through somatodendritic KARs, leading
to the paradox of KA inducing both overflow (Frerking et al.,
1998; Cossart et al., 1998) and inhibition of GABA release. Pre-
synaptic and somatodendritic KARs seem to coexist, presenting
AC
B Figure 4. Kainate Depresses HippocampalInhibition and Generates Epileptic Activity
In Vivo
(A) Arrangement of recording and stimulating
electrodes in vivo. In this experiment, a micro-
dialysis probe implanted in the region allowed
kainate to be slowly introduced into the extracel-
lular fluid. The degree of GABAergic inhibition
could be tested by the paired-pulse test, recording
field potentials from the CA1 pyramidal layer
through an extracellular electrode.
(B) Stimulation of the Schaffer collateral pathway
evokes the synchronous firing of a large number of
CA1 pyramidal cells (the sharp negative wave
indicated by an asterisk in the first evoked poten-
tial). This initial firing of the neuronal population
activates a population of inhibitory interneurons
that feedback onto the CA1 pyramidal neurons,
such that a second stimulus arriving during
the inhibitory phase (40 ms later) is unable to
induce CA1 neuron firing, evident by the absence
of a population spike in response to the second
stimulus under control conditions. After perfusion
of kainate through the dialysis probe (3 mM in the perfusate, probably 10% of this concentration reaches the extracellular fluid), the population spike in the
second response progressively develops, indicating a failure in the inhibition of pyramidal cells.
(C) After prolonged perfusion of kainate, ongoing epileptic activity develops that is characterized by the presence of interictal spikes in the EEG. The insert in
yellow represents a 1 s period over an expanded time base (modified from Rodrı´guez-Moreno et al., 1997).
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using different signaling pathways (Rodrı´guez-Moreno et al.,
2000; Mulle et al., 2000; Christensen et al., 2004; Maingret
et al., 2005). Thus, while somatodendritic KARs mediate part of
the synaptic input from Schafer collaterals, presynaptic KARs
are activated by synaptically released glutamate and they
reduce the inhibitory input to pyramidal cells (Min et al., 1999).
Thus, KARs play a fundamental role in the performance of
neuronal circuits, as exemplified in the hippocampus.
As for other aspects of KAR activity, the mechanism by which
KARs modulate inhibitory input to pyramidal neurons is not free
of controversy. It has been reported that inhibition of GABA
release from CB1 receptor-expressing interneurons induced by
KAR activation depended, at least in part, on cannabinoid-1
(CB1) and GABAB receptors strategically situated at the presyn-
aptic GABA boutons (Lourenc¸o et al., 2010, 2011). It was
proposed that synaptically released glutamate induced the post-
synaptic release of endocannabinoids and the extracellular
accumulation of GABA. This conclusion contradicts the observa-
tion of the inhibitory effect of KA on GABA release in interneuron-
pyramidal cell pairs in the presence of antagonists of CB1 (e.g.,
AM251) or GABAB (e.g., CGP55845) receptors (Daw et al., 2010).
Perhaps these disparate conclusions may come from the com-
bined or independent antagonism of both types of receptors,
but even when both receptors were blocked, a fraction of inhibi-
tion of GABA release seems to rely on KAR activity (Lourenc¸o
et al., 2011). Whatever the fraction of GABA release affected
by KAR activation, one can consider that presynaptic KARs will
be activated by glutamate released during intense periods of
activity in vivo. This will result in the depression of GABA release,
likely leading to a state of overexcitability that could have impor-
tant consequences on the circuit performance, making it more
seizurogenic by dampening inhibition. Indeed, this has been
proven to occur in the hippocampus in vivo when a low concen-
tration of KA is slowly dialyzed into the extracellular fluid. This
causes a depression of synaptic inhibition and the appearanceof interictal epileptic spikes in the electroencephalogram (EEG)
(see Figure 4; Rodrı´guez-Moreno et al., 1997).
Evidence that presynaptic KARs mediate tonic inhibition of
GABAergic transmission has also been obtained from the hypo-
thalamic supraoptic nucleus, where it involves a PLC-dependent
metabotropic pathway (Bonfardin et al., 2010). During develop-
ment, tonic activation of presynaptic GluK1-containing KARs
also depresses GABA release from hippocampal MF in a G
protein- and PLC-dependent manner (Caiati et al., 2010). Thus,
regardless of the mechanism, there is a growing body of
evidence that activation of presynaptic KARs depresses
GABAergic transmission, either after exogenous agonist appli-
cation or through endogenous released glutamate. However,
paired recordings of interneurons and CA1 pyramidal cells also
show that endogenous activation of KARs can facilitate GABA
release at some synapses (Jiang et al., 2001). Further evidence
that presynaptic KARs exert such a facilitatory effect on GABA
release has been gathered from hippocampal interneurons
(Mulle et al., 2000; Cossart et al., 2001), aswell as in several other
regions of the CNS like the neocortex (Mathew et al., 2008) and
hypothalamus (Liu et al., 1999). In contrast to the inhibitory
effects, the facilitation of GABA release by presynaptic KARs is
likely to involve the conventional ionotropic activity of these
receptors (reviewed in Rodrigues and Lerma, 2012). This seems
to at least be the case for endogenous activation of KARs in the
hypothalamic supraoptic nucleus. It was shown in an elegant
study that the increase in the ambient levels of glutamate, either
associated to a physiological reduction in astrocyte cover or due
to the blockade of glutamate transporters, switches facilitation
to inhibition of GABAergic release (Bonfardin et al., 2010)
(Figure 3). Interestingly, while facilitation was prevented by phi-
lantotoxin (a blocker of Ca2+-permeable receptors), the inhibitory
effect involved PLC. Thus, the net result of activating presynaptic
KARs by endogenous glutamate may depend on the glutamate
concentration actually reaching the presynaptic KARs, which
will ultimately depend on the magnitude of glutamate spilloverNeuron 80, October 16, 2013 ª2013 Elsevier Inc. 299
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astrocyte uptake capacity.
This hypothesis is further substantiated by data from the cer-
ebellum, where bidirectional modulation of transmitter release
has also been found. Synaptically activated presynaptic KARs
facilitate and depress transmission at parallel fiber synapses
(Delaney and Jahr, 2002). Activation of presynaptic KARs by syn-
aptically released glutamate at parallel fibers facilitates gluta-
mate release to both interneurons (e.g., stellate or basket cells)
and Purkinje cells when these fibers are subjected to a regime
of low-frequency stimulation. By contrast, with high-frequency
stimulation, the synapses onto inhibitory interneurons are
depressed, while synapses at Purkinje cells are still facilitated.
Such differential sensitivities to the frequency of these two syn-
apses may regulate the excitation/inhibition balance of Purkinje
cells and, therefore, cerebellar output. Thus, at some structures,
KARs bestow computational properties to circuits according to
the activity regime of afferent inputs.
Presynaptic regulation of excitatory transmission by KARs has
been studied extensively at MF-CA3 synapses. At these synap-
ses, presynaptic KARs are implicated in the characteristic fre-
quency-dependent facilitation of MF excitatory transmission
(Schmitz et al., 2001; Lauri et al., 2001; Contractor et al., 2001;
Pinheiro et al., 2007), a phenomenon initially ascribed to the re-
sidual intraterminal calcium. Since KAR antagonists attenuate
the potentiation of the second EPSC during high-frequency
trains (e.g., 25 Hz; Schmitz et al., 2001), the synaptic activation
of presynaptic KARs must be quite fast (10–30 ms), indicating
that KARs should be found near the active zone. Indirect evi-
dence suggests that the facilitation of glutamate release may
occur through the depolarization of presynaptic terminals
(Schmitz et al., 2001) that should enhance action potential-driven
Ca2+ influx (Kamiya et al., 2002; Lauri et al., 2003). The reduction
of synaptic facilitation by a blocker of Ca2+-permeable KARs
(Lauri et al., 2003) also points to a contribution of direct Ca2+
entry through these receptor channels, although Ca2+ mobiliza-
tion from intracellular stores may also add to this use-dependent
facilitation of glutamate release (Lauri et al., 2003; Scott et al.,
2008). Nevertheless, these conclusions have been challenged
by the indication that presynaptic KARs are insufficient to facili-
tate glutamate release at MF-CA3 synapses, attributing the phe-
nomenon to the activation of recurrent CA3 network activity
(Kwon and Castillo, 2008). However, blockade of postsynaptic
KARs at MF-CA3 synapses with newly available compounds
(e.g., UBP310) had no effect on presynaptic facilitation (Pinheiro
et al., 2013), a result similar to that observed in double GluK4/
GluK5 mice, in which there is no deficit in short-term plasticity,
whereas postsynaptic KAR-mediated responses are totally lost
(Fernandes et al., 2009). Therefore, in the absence of further
evidence against it, it should be concluded that part of the syn-
aptic facilitation observed at MF-CA3 synapses is due to the
activation of presynaptic facilitatory KARs. Considering that pre-
synaptic KAR function has been assessed indirectly, direct elec-
trophysiological recording from these presynaptic structures
may clarify the issue of whether or not ionotropic facilitatory
KARs are present at MF boutons.
Conclusive evidence indicates that this mechanism imposes
associative properties to MF-LTP, since the activity in neigh-300 Neuron 80, October 16, 2013 ª2013 Elsevier Inc.boring MF synapses influences the threshold to induce LTP at
these synapses (Schmitz et al., 2003). NMDARs implement the
associative properties of LTP. However, the contribution of
NMDARs to the induction of LTP in the CA3 field is quite modest
and onemight think that the presence of KARs at these synapses
maintains the general properties of LTP unaltered.
While the facilitation of glutamate release has clear functional
implications, it remains unclear under what circumstances the
suppression of glutamate release by KARsmay fulfill a significant
role. Interestingly, it seems that during development, the inhibi-
tory modulation of glutamate release may shape synaptic prop-
erties (Lauri et al., 2006; see below), and it has been observed
that long and strong trains of afferent activity depress rather
than facilitate synaptic transmission (Schmitz et al., 2001), a
mechanism that may be active under physiological conditions.
Facilitation of glutamate release at MF-CA3 synapses is
mimicked by applying low concentrations of exogenous KA
(Schmitz et al., 2000; Kamiya and Ozawa, 2000). Higher concen-
trations of KA depress synaptic transmission not only at MF-CA3
synapses but also at synapses between Schaffer collaterals and
CA1 pyramidal cells (Chittajallu et al., 1996; Kamiya and Ozawa,
1998; Vignes et al., 1998; Frerking et al., 2001) and those of the
associational/commissural pathway terminating onCA3 neurons
(Salmen et al., 2012). This inhibition is accompanied by a reduc-
tion in presynaptic Ca2+ (Kamiya and Ozawa, 1998; Salmen
et al., 2012), and since it is sensitive to G protein blockers, this
inhibition is unlikely to involve presynaptic depolarization, but it
is more likely to be contingent on noncanonical signaling (Frerk-
ing et al., 2001; Negrete-Dı´az et al., 2006; Salmen et al., 2012).
The inhibition of glutamate release at Schaffer collaterals-CA1
synapses does not involve protein kinases but, rather, a mem-
brane-delimited action that probably involves the direct inhibi-
tion of presynaptic Ca2+ channels by G protein gb subunits (De
Waard et al., 1997). The inhibitory effects of KARs upon tonic
activation by endogenous glutamate at these two hippocampal
synaptic populations have been observed during development
and involve KAR metabotropic signaling (Lauri et al., 2005,
2006; Sallert et al., 2007). Tonic activation of presynaptic KARs
in the adult brain also inhibits glutamate release in the rat globus
pallidus, once again mediated by a presynaptic Gi/o-protein-
coupled and PKC-dependent mechanism (Jin and Smith, 2007).
What now seems clear is that presynaptic KARs modulate
transmitter release in a bidirectional manner: facilitation probably
occurs through their ionotropic activity, while inhibition seems to
involve noncanonical metabotropic signaling. It is possible that
the threshold to activate one or other KAR signaling pathways
would determine physiological responses. In summary, the pre-
synaptic modulation of both glutamate and GABA release
together with the postsynaptic regulation of neuronal excitability
clearly demonstrates that KARs are endowed with diverse
capacities. These activities enable them to fine-tune synaptic
function and regulate neuronal network activity in the adult brain,
bestowing them with a much broader role at synapses than the
simple transfer of information.
Role of Kainate Receptors during Development
KARs are expressed strongly in the brain during development in
a complex cell-type-specific manner. The properties of synap-
ses during development differ significantly from those at mature
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these changes.
The expression of KARs, and particularly of GluK1 subunits,
increases markedly and peaks during the first week of life in
rodents (Bahn et al., 1994). In immature hippocampal CA1 syn-
apses, the tonic activation of KARs by ambient glutamate keeps
the probability of release low (Lauri et al., 2006). However, a burst
of synaptic activity produces strongly facilitating postsynaptic
responses, a facilitation that is not only abolished in the presence
of a KAR antagonist but also later in development. Interestingly,
this change is recapitulated by inducing LTP and it seems that
the tonic stimulation of KARs by ambient glutamate is no longer
possible under each of these circumstances, changing the short-
term synaptic dynamics. It is possible that the lower ambient
glutamate contributes to the lack of tonic KAR activation after
the first postnatal week. However, it does seem that the affinity
of the receptor actually changes, making it less sensitive to the
agonist. Indeed, it has been claimed that a change in an isoform
of the GluK1 subunit in KARs is responsible for this lower affinity
(Vesikansa et al., 2012). The inhibition of synaptic release under
these circumstances seems to be mediated by noncanonical
KAR signaling. Another interesting situation in which a change
in the properties of KARs takes place during development is in
CA3 interneurons, where the firing rate is controlled by the
KAR-mediated tonic inhibition of IAHP during the first postnatal
week (Segerstra˚le et al., 2010). One more example of how
KARs may control network activity during development is pro-
vided by the reduced glutamatergic input to CA3 pyramidal cells
following tonic KAR activation and the simultaneous facilitation
of glutamate release onto CA3 interneurons (Lauri et al., 2005).
This action permits network bursting in the developing hippo-
campus. All in all, these data imply a role for KARs in driving
network activity during maturation, when synchronous neuronal
oscillations are important for the development of synaptic cir-
cuits (e.g., Zhang and Poo, 2001).
KARs also seem to contribute to the development of neuronal
connectivity by guiding the morphological development of the
neuronal synaptic network (i.e., the tracks and the formation of
early synaptic contacts). In GluK2-deficient animals, the func-
tional maturation of MF-CA3 synaptic contacts that normally
occurs between postnatal day 6 (P6) and P9 is delayed (Lanore
et al., 2012). In the early contact and rearrangement stages,
growth cone motility is essential for the axon to explore its envi-
ronment and find its appropriate synaptic targets (Goda and
Davis, 2003). In the developing hippocampus, KARs bidirection-
ally regulate the motility of filopodia in a developmentally regu-
lated and concentration-dependentmanner, increasing filopodia
motility upon activation with low concentrations of KA and
decreasing it in the presence of high concentrations of KA
(Tashiro et al., 2003). These data support a two-step model of
synaptogenesis, whereby low concentrations of glutamate early
in development enhance motility by activating KARs to promote
the localization of synaptic targets. Having established the
nascent synapse, the increase in glutamate concentrations as
a consequence of the reduction in extracellular volume may
then reduce filopodia motility, prompting stabilization of the con-
tact (Tashiro et al., 2003). This model is also consistent with the
observation that filopodia motility is related to the free extracel-lular space in which it is found, displaying lower motility as the
free extracellular space diminishes (Tashiro et al., 2003). In this
regard, KARs may represent sensors for the axonal filopodia to
probe their immediate environment and, hence, it may be essen-
tial for guidance and the formation of synaptic contacts.
Together, these data demonstrate a critical role for KARs in the
development of synaptic connectivity and in the maturation of
neuronal networks. In particular, how altering KAR activity during
development highlights the key role fulfilled by these receptors
when synaptic networks are established. However, we are only
just beginning to understand the role of KARs in neuronal devel-
opment and maturation, and the exact mechanisms underlying
such events remain not defined.
Putative Roles of KARS in Brain Disease
Abnormalities in glutamatergic neurotransmission are consid-
ered to be an important factor contributing to neurodegenerative
and mental disorders (e.g., Frankle et al., 2003). Kainate recep-
tors have been linked to a number of brain disorders such as
epilepsy, schizophrenia, and autism, yet their role in brain pathol-
ogies appears at times contradictory. Although the experimental
data now available indicate a number of putative roles for KARs
in mood disorders, the data available are not free of caveats (see
Table 2).
Mood Disorders
Perhaps the most fascinating results come from the studies that
potentially connect KARs with schizophrenia and bipolar disor-
ders. On the one hand, postmortem studies provided evidence
of a change in KAR subunits in schizophrenic brains (Benes
et al., 2001), although these were not corroborated in other
studies. For instance, a careful quantitative study of glutamate
receptor mRNA expression failed to detect any change in KAR
subunit expression in dissected thalamic nuclei from the brains
of subjects diagnosed with schizophrenia (Dracheva et al.,
2008). On the other hand, postmortem gene expression profiling
indicated that in the hippocampus, parahippocampus, and the
prefrontal cortex, at least, there is a decrease in the mRNA-
encoding GluK1 subunits (Scarr et al., 2005). Obviously it is
difficult to evaluate the availability of protein from mRNA quanti-
fication, and given the absence of a specific GluK1 antibody,
these data await further verification.
Recent GWAS studies of thousands of cases indicated a poly-
genic basis to schizophrenia, identifying SNPs that are shared
with bipolar disorder but not with other nonpsychiatric diseases
(Ripke et al., 2011; Sklar et al., 2011). The common involvement
of several genes in a disease complicates the reproduction of
those diseases in experimental models, as it would not be ex-
pected that a single mutation could fully reproduce the syn-
drome. In the case of KARs, this is exemplified by the fact that
an SNP for Grik4 (rs1954787) is more abundant in subjects re-
sponding to antidepressant treatment with a serotonin uptake in-
hibitor (citalopram) than in patients that do not (Paddock et al.,
2007). This SNP is located in the 30 region of the first intron of
Grik4 gene and, while it does not directly affect the protein
sequence, it seems to alter gene expression. Similarly, there
are data suggesting that Grik3 might be a susceptibility gene
for major depressive disorder, whereby the SNP T928G
(rs6691840) that causes an S to A alteration in the extracellularNeuron 80, October 16, 2013 ª2013 Elsevier Inc. 301
Table 2. KARs Most Salient Linkage to Mood Disorders
Gene Data Linked Disease
Behavioral
Test in KO References
Grik1 Upregulated expression Epilepsy No Sander et al., 1997; Izzi et al., 2002; Li et al., 2010; Lucarini et al., 2007
Grik2 Modest linkage Autism No Jamain et al. 2002; Shuang et al., 2004; Szatmari et al., 2007; Freitag 2007;
but see Dutta et al., 2007
Grik2 Deletion of exons 7 and 8 Mania, mild mental
retardation
No Motazacker et al., 2007; Shaltiel et al., 2008; Lanore et al., 2012
Grik2 Mapping susceptibility locus Schizophrenia Yes Beneyto et al., 2007; Shaltiel et al., 2008; but see Shibata et al., 2002, 2006
Grik2 mapping Huntington No MacDonald et al., 1999; Chattopadhyay et al., 2003; but see Lee et al., 2012
and Diguet et al., 2004
Grik3 SNP T928G (rs6691840) Schizophrenia No Begni et al., 2002; Kilic et al., 2010; Ahmad et al., 2009;
Grik3 SNP T928G (rs6691840) Major depression No Schiffer and Heinemann, 2007; Wilson et al., 2006
Grik4 Treatment response Depression No Paddock et al., 2007
Grik4 14 bp deletion/insertion
variant
Bipolar disorder Yes Pickard et al., 2008; Catches et al., 2012; Lowry et al., 2013
Grik4 SNPs rs2282586 and
rs1944522
Protection against
Schizophrenia
Yes Pickard et al., 2006
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Reviewdomain of GluK3, is in linkage disequilibriumwith recurrent major
depressive disorder patients (Schiffer and Heinemann, 2007)
and subjects with schizophrenia (Begni et al., 2002; Kilic et al.,
2010; Djurovic et al., 2009; Ge´cz et al., 1999). Indeed, the distri-
bution of the GG homozygous genotype was significantly higher
in schizophrenia patients than in controls (Ahmad et al., 2009;
Kilic et al., 2010). However, this amino acid change does not
have any detectable functional consequence in the receptor
(Schiffer et al., 2000), although it could convey aberrant gene
dosage and/or unequal allele expression (Schiffer et al., 2000;
Wilson et al., 2006). Indeed, mRNAs for GluK3 and other gluta-
mate receptors are reduced in the frontal cortex of schizophrenic
subjects (Sokolov, 1998; but see Meador-Woodruff et al., 2001).
As for other subunits, GluK3 gene expression is developmentally
regulated and aberrant gene dosage during development may
impact disease in adulthood (Wilson et al., 2006). Thus, further
experiments using transgenic animals are warranted.
A clear example of gene dosage is provided by trisomy of
chromosome 21, leading to Down syndrome. Grik1, the gene
coding for GluK1 subunits, is located on human chromosome
21q22.1, and genetic mapping places Grik1 in the vicinity of
genes coding for APP and super oxide dismutase (SOD1; Gregor
et al., 1994). However, linkage analysis failed to detect any asso-
ciation with familial amyotrophic lateral sclerosis and there are
no data indicating any role forGluK1 gene disequilibrium dosage
in Down syndrome.
Based on multiple regression analyses, it appears that the
effects of anxiety and depression treatment are significantly
and independently associated with the Grik4 gene (Paddock
et al., 2007). An association was also observed in female patients
withmarkers inGrik1. Together, these data indicate that reduced
expression of Grik1, Grik4, and other genes encoding KAR sub-
units could be implicated in mood disorders (but see Li et al.,
2008). However, the sign of this implication is clearly elusive
and these linkages may be circumstantial given that causal
mutations have not yet been identified through linkage or candi-
date gene association studies. It is becoming clear that no con-302 Neuron 80, October 16, 2013 ª2013 Elsevier Inc.clusions can be reached without more precise information of the
role of these subunits in general brain physiology. However,
recent studies using experimental models have started to assess
how the absence of one of these genes affects behavior. The
ablation ofGrik4 in mice results in marked hyperactivity (Catches
et al., 2012; Lowry et al., 2013), one of the endophenotypes of
patients with bipolar disorders, which has been interpreted as
if lack of GluK4 activity has an anxiolytic and antidepressive-
like effect (Catches et al., 2012). Anxiety and depression are con-
current with bipolar disorders, and these data would in principle
support the hypothesis that GluK4 hyperactivity could be a hall-
mark of bipolar phenotypes. However, genetic data from bipolar
patients seem to refute this conclusion. In a case control associ-
ation study, two SNP haplotypes (rs2282586 and rs1944522)
exhibited a protective effect against bipolar disorder in a diverse
Scottish population (Pickard et al., 2006). Subsequent studies
identified a 14 bp deletion/insertion variant in the 30 UTR of the
Grik4 gene in subjects carrying a protective haplotype with a sig-
nificant association to the risk of bipolar disorders (Pickard et al.,
2008). Surprisingly, the deletion allele was negatively associated
with bipolar disorder and it resulted in an increase in the abun-
dance of both GluK4 mRNA (Pickard et al., 2008) and protein
in the hippocampus and prefrontal cortex (Knight et al., 2012).
This resulted from the fact that the mRNA bearing the deletion
seems to be more stable and persistent than that bearing the
insertion, resulting in an increase in GluK4 protein of up to
90% in the hippocampus and 40% in the cortex of the human
brain.
Consequently, one would expect that mice either deficient for
this gene or with GluK4 hypoactivity would display behavior
associated to bipolar disorders rather than expressing an antian-
xiolytic or antidepressive phenotype. Indeed, in the forced
swimming test, immobility is reduced by a number of antide-
pressant drugs in normal mice, indicating that such immobility
may be read out of depressive-like behavior. As in GluK4 KO
mice, GluK2-deficient animals show less immobility than wild-
type (WT) mice, although chronic lithium treatment reduced
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WT mice (Shaltiel et al., 2008). If the lack of GluK2 were antide-
pressive, it should occlude the action of lithium, as lithium has
no effect in normal subjects. Therefore, it is possible that less
immobility would reflect anxiogenicity rather than less depres-
sion. Actually, this kind of test of behavioral despair was
designed as a test for the primary screening of antidepressant
drugs (Porsolt et al., 1977). Therefore, when using this test, it is
difficult to deduce an antidepressive state through less immo-
bility without directly checking the action of the antidepressants.
Nevertheless, mice in which Grik4 is deleted also display a
schizophrenic phenotype and, indeed, GluK4 KO mice show
impaired paired-pulse inhibition, mirroring one of the endophe-
notypes of patients with schizophrenia (Lowry et al., 2013).
These data are in keeping with the presence of three SNPs of
the Grik4 gene in a patient with chronic schizophrenia and mild
mental retardation (Blackwood et al., 2007, 2008; Pickard
et al., 2006). This patient was found to present a complex rear-
rangement of a segment of chromosome 11, involving chromo-
somes 2 and 8. The Grik4 gene was disrupted at a breakpoint
situated at 11q23.3 and the expected outcome was the trunca-
tion of all putative transcripts such that the protein encoded
would not be functional (Blackwood et al., 2007; Pickard et al.,
2006). This means that knocking out Grik4 would result in symp-
toms of schizophrenia and/or mental disability. Indeed, the
GluK4 KO does present learning deficits (Lowry et al., 2013;
but see Catches et al., 2012). Interestingly, treatment with neuro-
leptic drugs seems to restore levels of GluK4 mRNA expression
that are abnormally low (ca. 50%) in the frontal cortex of schizo-
phrenics (Sokolov, 1998). Clearly, SNPs found in the Grik4 gene
as markers of schizophrenia and bipolar disorders confirm a role
for this gene as a risk factor for mood disorders. The SNPs vary
with the disease, with SNPs at the center of the gene at chromo-
some 6q11 associated with schizophrenia and SNPs at the
gene’s 30 end associated with bipolar disorders.
Clarification of aspects mentioned above is critical for envi-
sioning therapeutic opportunities. On the one hand, data from
patients suggest that a pharmacologically mediated increase in
KAR activity might be beneficial to protect against bipolar disor-
ders, while on the other hand, behavioral data from mice (e.g.,
GluK4-deficient mice) may open the door to therapeutic oppor-
tunities for antagonists (e.g., of GluK4). However, this latter
approach would be detrimental to other phenotypes, such as
schizophrenia. The uncertainty of interpreting behavioral data
in mice must also be born in mind and, as mentioned above,
reduced immobility of KO mice in the forced swimming test
has been interpreted as antidepressant in some cases and as
a sign of mania in others.
A significant decrease in GluK2 mRNA expression has been
reported in schizophrenic subjects (Porter et al., 1997). Interest-
ingly, this gene maps close to a locus of schizophrenia suscep-
tibility on chromosome 6 (6q16.3-q21) (Bah et al., 2004),
although no association between this gene and schizophrenia
could be demonstrated after studying 15 SNPs evenly distrib-
uted over the entire Grik2 region, ruling out a major role of
GluK2 in the pathogenesis of schizophrenia (Shibata et al.,
2002). However, several genome-wide studies have shown sig-
nificant linkage between bipolar disorders and chromosome6q21 (McQueen et al., 2005), where Grik2 maps, and GluK2
mRNA expression is also reduced in the brain of bipolar patients
(Beneyto et al., 2007). Interestingly, Grik2 KO mice exhibit a
variety of behaviors, including hyperactivity, aggressiveness,
and sensitivity to psychostimulants, reproducing in mice the
behavioral symptoms of mania in humans (Shaltiel et al., 2008).
However, it is not currently possible to infer whether GluK2 is
involved in the pathophysiology of mania and/or susceptibility
to bipolar disorders, or if it is just related to some features of their
symptoms.
Mental Retardation
In one of the eight genomic loci linked to nonsyndromic auto-
somal recessive mental retardation in a study of 78 consanguin-
eous Iranian families, gene defects were revealed precisely in an
interval on chromosome 6116.1-q21. This locus contains 25
annotated genes, including Grik2, which was screened for
DNA mutations in patients with mental retardation. Only one
single nonpolymorphic sequence change was detected, involv-
ing a deletion that removed exons 7 and 8 of the Grik2 gene
(Motazacker et al., 2007). Although a truncated GluK2 subunit
was generated, it was unable to contribute to functional recep-
tors, suggesting a severe hypofunction in glutamatergic sig-
naling through KARs that would alter local brain circuits and
induce cognitive impairment. An attractive hypothesis proposed
in this study was that defects in GluK2 signaling may be impor-
tant for correct circuit maturation in areas important for higher
brain functions, such as the hippocampus. This hypothesis
was recently tested in GluK2-deficient animals in which a delay
in the functional maturation of MF to CA3 synaptic contacts
occurs between P6 and P9 (Lanore et al., 2012). Although this
transient defect in synaptic transmission may be critical for cor-
rect postnatal development, it is not clear how it may affect hip-
pocampal performance in adults beyond the fact that the
absence of KARs at MF to CA3 synapses alters the integrative
properties of the hippocampal trisynaptic circuit, which is impor-
tant for memory acquisition in novel environments and some-
times for memory recall (Nakashiba et al., 2008).
Grik2 has also been associated with autism (Jamain et al.,
2002; Shuang et al., 2004; Freitag, 2007). However, these find-
ings were inconclusive and could not be substantiated by further
genome-wide linkage studies in which only a modest positive
linkage could be seen in families containing females (Szatmari
et al., 2007). Indeed, other studies also failed to find associated
markers in individuals with autism spectrum disorder (Dutta
et al., 2007) and GluK2 KO mice have not been studied in terms
of this pathology.
Huntington Disease
A number of studies have shown that glutamine repeats in Hun-
tington disease (HD) only account for 50%–60% of the variance
at the age of onset (e.g., Snell et al., 1993). This fact prompted a
search for functional consequences in the age of onset of poly-
morphisms associated with HD chromosomes. Among other
genes, and given that excitoxicity is considered a potential
mechanism for the cell death seen in HD, the Grik2 gene was
examined for its potential influence on the age of onset, particu-
larly since it maps to chromosome 6q. More than 4% of the total
variance could be attributed to variation in the GluK2 genotype,
representing 13% of the variance in the age of onset of HD notNeuron 80, October 16, 2013 ª2013 Elsevier Inc. 303
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fore, it was concluded that a younger onset of HD is in linkage
disequilibrium with a variant of GriK2 or another gene in the re-
gion (MacDonald et al., 1999; Chattopadhyay et al., 2003). To
reproduce these data in a larger population, the HDCAG repeats
and the Grik2 TTA repeats were genotyped in a large (>2,900)
population of HD subjects (Snell et al., 1993; Lee et al., 2012).
No evidence of an influence of Grik2 polymorphisms on age at
motor onset was found and, therefore, there was no support
for the role of Grik2 as a genetic modifier of the age of onset in
HD. Similarly, a study of the susceptibility of GluK2-deficient
mice to 3-nitropropionic acid, a drug used to induce metabolic
failure and secondary excitotoxic HD-like damage, was also
inconclusive (Diguet et al., 2004). Therefore, despite efforts to
link GluK2 to HD, it seems unlikely that KARs are involved in
the direct pathogenesis of this disease.
Epilepsy
There are several lines of evidence strongly suggesting that
KARsmight be involved in the excitatory to inhibitory imbalances
linked to epilepsy. Actually, KA injection has served as an animal
model that reproduces details of human temporal lobe epilepsy
(TLE). The inhibition of GABA release and the activation of post-
synaptic KARs might account for the acute epileptogenic effect
of KA (Rodrı´guez-Moreno et al., 1997), although these events do
not explain the chronic epilepsy generated months after KA
treatment. Actually, the seizures provoked initiate a number of
molecular changes and morphological rearrangements in struc-
tures with a low epileptogenic threshold, such as the hippocam-
pus. For instance, it is well known that sprouting of glutamatergic
fibers takes place in both the KA model of TLE and in human
patients and, accordingly, a large number of aberrant synapses
are established de novo. These functional aberrant synapses
made on granule cells of the dentate gyrus are sprouted MFs
and they incorporate KARs, which provide a substantial compo-
nent of the excitatory input (Epsztein et al., 2005). Thus, aberrant
KAR-operated synapses formed under pathological conditions
represent a morphological substrate likely to participate in the
pathogenesis of TLE (Artinian et al., 2011). The data available
from human epileptic tissue indicates an upregulation of GluK1
in the hippocampus of pharmacoresistant TLE patients (e.g., Li
et al., 2010), suggesting that rearrangements in neural circuits
involving KARs could also take place in humans suffering epi-
lepsy. Although these data should be considered with care due
to the poor specificity of some KAR antibodies (e.g., GluK1), it
raises the possibility of designing antiepileptic therapies based
on the antagonism of KARs.
Consistent with KARs influencing this imbalance, the genetic
elimination of GluK2 subunits in mice reduced their sensitivity
to develop seizures after KA injections (Mulle et al., 1998), illus-
trating that these receptors contribute to the establishment of
overexcitability by exogenous KA that leads to epilepsy. Simi-
larly, exogenous KA reduced GABA release in slices (Clarke
et al., 1997; Rodrı´guez-Moreno et al., 1997), dramatically pre-
venting the recurrent inhibition of hippocampal principal neurons
in vivo and provoking epileptic activity (Rodrı´guez-Moreno et al.,
1997). According to these data, constituting the strongest evi-
dence of the potential therapeutic utility of KARs, a consortium
of academic and industry groups (Smolders et al., 2002) showed304 Neuron 80, October 16, 2013 ª2013 Elsevier Inc.that antagonists of GluK1 (i.e., LY377770 and LY382884) prevent
the development of epileptic activity in the CA3 area of hippo-
campal slices in a model of pilocarpine-induced epileptiform
activity. Interestingly, GluK1 antagonists were equally effective
in abolishing epileptic activity in slices and in preventing seizures
as well as in abolishing seizures once established in vivo. In
contrast, others (Khalilov et al., 2002) have indicated a potential
for GluK1 agonists as antieplieptic based on the overinhibition
largely mediated by GluK1-containing receptors, which are
enriched in hippocampal interneurons.
The muscarinic agonist pilocarpine is used as a standard
model to generate epileptiform activity in order to evaluate the
potential of anticonvulsant drugs (cf. Smolders et al., 2002 and
references therein). One of the advantages of this model is that
it does not involve direct stimulation of KARs, thereby allowing
the evaluation of the contribution of tonic KAR activation by
ambient glutamate to the epileptic phenomena. It is likely that
multiple mechanisms may account for the involvement of
KARs in epilepsy. It is possible that the glutamate released due
to circuit hyperactivity may provoke both tonic activation of
CA3 neurons and KAR-mediated depression of synaptic inhibi-
tion. These two actions would be sufficient to generate a drastic
imbalance between excitation and inhibition, leading to hippo-
campal seizures. A similar mechanism has been invoked in the
amygdala to account for the therapeutic effects of topiramate
(Braga et al., 2009), an approved antiepileptic medicine.
A linkage study of 20 families found a significant excess of the
Grik1 tetranucleotide polymorphism (nine ‘‘AGTA’’ repeats) in
members of families affected by idiopathic juvenile absence
epilepsy (Sander et al., 1997). This allelic variant of Grik1 prob-
ably confers susceptibility to juvenile absence epilepsy, when
superimposed on a background of strong polygenic effects.
The tetranucleotide polymorphism maps to the noncoding re-
gion of the gene, close to regulatory sequences, and although
it does not seem to affect receptor structure (Izzi et al., 2002),
it could alter gene expression. However, as there is no evidence
of this to date, this association may also be due to a hypothetical
epilepsy gene in this region in linkage disequilibrium with Grik1
tetranucleotide repeats (Lucarini et al., 2007). Despite all the
evidence linking KARs to epilepsy, to our knowledge no anti-
epileptic drugs have been developed to date based on KAR
antagonists.
Pain
KARs are expressed strongly in DRG cells and dorsal horn neu-
rons, pointing to a specific role for these receptors in sensory
transmission and pain. Indeed, KARs were targeted as potential
elements involved in pain transmission and kainate was demon-
strated to depolarize primary afferents (Agrawal and Evans,
1986). Moreover, a pure population of KARs was initially isolated
from DRG neurons that are likely to be C fiber nociceptors
(Huettner, 1990). Molecular and electrophysiological character-
ization of these neurons led us to conclude that these DRG
KARs are made up of heteromeric GluK1 and GluK5 subunits
(Sommer et al., 1992; Bahn et al., 1994; Rozas et al., 2003),
and since glutamate-induced currents are lost in GluK1-deficient
mice, this appears to be the only iGluR expressed in these cells
(Mulle et al., 2000; Rozas et al., 2003). Although pain perception
cannot be properly considered a disease, persistent or recurrent
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Figure 5. Diagram Illustrating How KARs Could Influence Cognitive
Functions by Modifying Key Functional Features of Neuronal and
Circuit Activity
Any alteration in the regulation of these activities, including circuit maturation
during development, may provoke sufficient disequilibrium as to lead to a
disease state.
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Reviewpain is associated to a number of disorders of distinct origins and
pathophysiological bases, including neuropathic pain. Initial
support for the involvement of KARs in pain transmission came
from the fact that several KAR antagonists possess analgesic
activity in a number of animal models of pain. For instance,
SYM 2081 increases the latency of escape in the hot plate and
chronic constriction injury tests, presumably acting as a func-
tional antagonist (Sutton et al., 1999), whereas the antagonist
of GluK1-containing receptors, LY382884, decreases the fre-
quency of paw licking induced by the subcutaneous injection
of formalin (Simmons et al., 1998). In keeping with these results,
the ablation of Grik1 gene mitigates pain-associated behavior
(Ko et al., 2005; see Bhangoo and Swanson, 2013 for a review
and references therein).
Interestingly, the activation of primary afferent sensory fibers
produces a kainate receptor-mediated EPSC on the dorsal
horn neurons (Li et al., 1999). As in the CNS, these synaptic re-
sponses are characterized by slow onset and decay time con-
stants. A remarkable feature of these KAR-mediated EPSCs is
that they can only be elicited upon nerve stimulation at intensities
strong enough to activate the high-threshold Ad and C fibers.
This feature raises the possibility that KARs may be exclusively
involved in nociceptive transmission at this level, a hypothesis
that received significant support when opiate agonists were
shown to reduce the amplitude of the KAR-mediated EPSC in
dorsal horn neurons (Li et al., 1999). In addition, this receptor
subtype is also expressed by trigeminal neurons (Sahara et al.,
1997) and KARs are generally expressed along nociceptive path-
ways, from DRG neurons to the cortex (see Wu et al., 2007 for a
review). The strong indications that GluK1 antagonists modulate
pain perception have led to several clinical trials to validate KARs
as therapeutic targets for pain treatment (reviewed by Bhangoo
and Swanson, 2013). While some of these demonstrated certain
efficacy, and positive results were reported in phases I and II for
migraine, postoperative pain, and analogous cases, these ther-apeutic trials appear to have been abandoned (see Bhangoo
and Swanson, 2013 and references therein).
Thus, the genetic linkage of KAR subunits to diseases are
extremely illustrative as to the diseases that may be influenced
or triggered by KARs, represent promising lines for further
studies into their mechanistic causes. However, much work re-
mains to be done before definitive conclusions can be drawn
regarding the exact roles of KARs in brain disease.
Perspective
It is now apparent that KARs play different roles in synaptic
transmission and its modulation to those fulfilled by other gluta-
mate receptors, such as AMPARs and NMDARs (see Figure 5),
yet there is still much to be learned concerning the role of
KARs in brain performance. Several functional implications
directly emanate from the role played by KARs as ion channel
forming receptors at synapses, including a role in short- and
long-term synaptic plasticity. New and unexpected roles for
KARs come from their capacity to signal though noncanonical
metabotropic pathway. Although the importance of both
signaling modes has been demonstrated in neuronal physiology,
it is unclear which may be more relevant and under which cir-
cumstances, something we hope will be revealed in the near
future. Similarly, it remains unclear which subunits may be
responsible for coupling to G proteins and how an ion channel
couples to and activates a G protein. These questions, relevant
to fully understand KARs, await further advances.
It is also necessary to more strictly examine the role of KARs
in brain disease, as indicated by the linkage of SNPs and muta-
tions in KAR encoding genes to several devastating diseases,
such as schizophrenia and bipolar disorders, themost promising
syndromes linked to KAR malfunction. Such studies should
benefit from the already abundant information of the roles
played by KARs in synaptic physiology, and the availability of
KO and transgenic models will be particularly beneficial in this
enterprise. Nevertheless, new models are still to be developed.
These experiments will reveal how KARs participate in normal
behavior and whether they are suitable targets for therapeutic
interventions.
The plethora of proteins able to interact with KARs, some of
them demonstrated to be true ancillary proteins, opens a new
field of research to analyze their role not only in pacing affinity
and channel gating but also in the polarized trafficking of these
receptors. How do they get into the presynaptic terminals?
How do they get into the synaptic spines? Is there a specific
role for abundant extrasynaptic KARs? Are all these protein-
protein interactions regulated by neuronal activity or any other
functional factors?
In summary, after 20 years of research following their func-
tional identification in CNS neurons, KARs remain vaguely
defined entities. There is a lot of information available but under-
standing the functions of KARs still lags behind that of other
glutamate receptors and a comprehensive model is still lacking.
The potential of these receptors as targets for new therapeutic
interventions is extensive and could well represent just the tip
of an iceberg. The detailed study of currently available KAR-defi-
cient mice and the development of new animal models (e.g.,
conditional KOs and mice overexpressing KARs) should fuelNeuron 80, October 16, 2013 ª2013 Elsevier Inc. 305
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Reviewprogress in this area, perhaps unraveling how these receptors
may more efficiently serve as therapeutic targets.ACKNOWLEDGMENTS
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